First Immunotherapy Approved for Basal Cell Carcinoma Objective responses in 27% of previously treated patients who received cemiplimab Feb 10, 2021
FDA Panel Slows the Roll for Pembrolizumab in Breast Cancer Advisory committee: Wait for more data before considering neoadjuvant indication Feb 09, 2021
Has Pembrolizumab Finally Met an Indication FDA Doesn't Like? Agency staff skeptical of data in early breast cancer Feb 08, 2021
Anti-CD20 Drugs Tied to Severe COVID in Cancer Patients Plus: Active chemo treatment may not be a COVID risk factor Feb 05, 2021
Brain Tumor Risk Upped With Synthetic Progestogen Absolute risk still low, however, and product not currently approved in U.S. Feb 03, 2021
Optimizing Neoadjuvant Therapy for Breast Cancer ASCO guideline covers patient selection, treatment options, follow-up Feb 02, 2021
Dustin Diamond's Small Cell Lung Cancer "Saved by the Bell" actor diagnosed after exhaustive testing Feb 02, 2021
KRAS Inhibitor Continues to Impress in NSCLC Sotorasib yielded deep and durable responses in over one-third of patients Feb 01, 2021
Nab-Paclitaxel as Possible Option for Relapsed NSCLC Noninferior to docetaxel for OS, though impact on clinical practice questioned Feb 01, 2021
AGA Updates Guidelines for Refractory H. Pylori New info stresses knowing patients' antibiotic exposure and doing drug susceptibility testing Feb 01, 2021
Should COVID-Strained Centers Hit Pause on Lung Cancer Screening? A debate on what stopping scans would do to health systems, patients Feb 01, 2021
Promising Data for Preop Checkpoint Inhibition in NSCLC Major response rate of 21%, encouraging survival with single-agent atezolizumab Jan 31, 2021
First-Ever Survival Bump in Relapsed Mesothelioma OS, PFS improved with nivolumab, but questions remain about alternatives, biomarkers Jan 30, 2021
Dual Checkpoint Blockade No Help in PD-L1-High NSCLC Single-agent pembrolizumab wins out as first-line therapy for advanced disease Jan 30, 2021
COVID Affects Cancer Care, Patients' Mental Health Studies: fewer diagnoses, more severe disease, worse outcomes, distressed patients Jan 29, 2021
Preventive Approach to C-Section Bleeding Pans Out in Trial Treatment lowered risk of early blood loss and transfusion, but not more severe hemorrhage Jan 29, 2021
Whole-Pelvis Tops Prostate-Only RT in High-Risk Disease Practice impact may hinge on knowledge versus clinical bias Jan 28, 2021
Officials Investigate Physician's Death After COVID Vaccination Onset of rare blood disorder should not be interpreted as causal, experts say Jan 27, 2021
JAK Inhibitor Misses Endpoint in Safety Study. Now What? Major blow to popular class of oral rheumatology drugs Jan 27, 2021
Montana Oncologist Fired for Misdiagnosing, Overtreating Patients But some rally around him Jan 26, 2021
Telehealth's Security Problem; Virtual Cancer Care; Post-Pandemic Teladoc Emerging trends in telemedicine and telehealth Jan 25, 2021
Ozempic Seeking High Dose OK; Thyroid Cancer Overdiagnosed in Kids? News and commentary from the endocrinology world Jan 24, 2021
Aspirin and CRC Risk: A Curious Age Connection Implications for prophylactic recommendations, researchers say Jan 21, 2021
Cancer and COVID; Booze and Cancer; 'Screech' Starts Chemo News, features, and commentary about cancer-related issues Jan 21, 2021
Kardashian Makeup Artist Hrush Achemyan's Ovarian Cancer Beauty influencer reveals diagnosis Jan 21, 2021
Oncotype DX Misses on Breast Cancer Risk in Black Women Accuracy of 21-gene recurrence score worse compared with white women Jan 21, 2021
Not Just BRCA: Large Studies ID Other Key Breast Cancer Risk Genes Implications for screening and other risk-management strategies, researchers say Jan 20, 2021
Preop RT Flunks Test in Borderline Pancreatic Cancer Chemotherapy alone judged efficacious but not chemoradiation Jan 20, 2021
Drug Hits Target in Advanced Biliary Cancer Responses in up to a third of patients with FGFR inhibitor infigratinib Jan 19, 2021
Liquid Biopsy Predicts Colon Cancer Relapse Months Before CT Test for ctDNA outperformed existing biomarker, may help guide therapy Jan 17, 2021
New Target to Attack in Stomach Cancer PFS, OS improved with fibroblast growth factor receptor inhibitor in non-HER2 disease Jan 16, 2021
Ethics Consult: Refuse Treatment for Dictator? MD/JD Weighs In You voted, now see the results and an expert's discussion Jan 15, 2021
Copay Assistance Programs Help Patients but Confuse Them Too Insurers keep track of their use and in some cases won't apply them to patient deductibles Jan 13, 2021
Nuanced View of Oral Sex, HPV+ Oropharyngeal Cancer Age at first oral sex, 'intensity,' number of partners all influence risk Jan 13, 2021
Is This Really Cancer? Movement builds to classify Gleason 6 prostate lesions as nonmalignant Jan 09, 2021
Most Women Satisfied With 'Going Flat' After Mastectomy Lack of surgeon support key factor in later dissatisfaction, study shows Jan 08, 2021
Medicare's 'Most Favored Nation' Drug-Pricing Rule in Limbo Rule affecting Part B drugs was to take effect Jan. 1 but was stopped by federal court orders Jan 07, 2021
Targeted Combo Fails in EGFR-Mutant NSCLC Osimertinib-bevacizumab no better than osimertinib alone Jan 07, 2021
Baby Boys Get Cancer From Mom During Birth Report highlights potential fetal implications of undiagnosed maternal cervical cancer Jan 06, 2021
PARP Inhibitors Linked With Blood Cancer Risk Incidence of MDS/AML under 1%, but further investigation warranted as indications broaden Dec 28, 2020